- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.09. | Annexin Pharmaceuticals AB: Annexin appoints world-leading ophthalmology experts to Medical Advisory Board | 96 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has appointed a Medical Advisory Board in Ophthalmology. The independent clinical experts in the Board will act as key advisors to the Annexin team advancing the clinical... ► Artikel lesen | |
| 07.08. | Annexin Pharmaceuticals AB: Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO | 139 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start a clinical Proof of Concept phase 2a study with the drug candidate ANXV... ► Artikel lesen | |
| 28.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 28.05.2025 | 1.285 | Xetra Newsboard | The following instruments on XETRA do have their first trading 28.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.05.2025
Aktien
1 CNE100006XS6 Jiangsu Hengrui Pharmaceuticals... ► Artikel lesen | |
| ANNEXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.05.2025 | 639 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.05.2025ISIN NameCA42841L1085 HI-VIEW... ► Artikel lesen | |
| 27.05. | XFRA ISIN CHANGE | 621 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA82888R1055 Simply Better Brands Corp. 27.05.2025 CA89778A1003 Trubar Inc. 28.05.2025 Tausch 1:1SE0009664154 Annexin... ► Artikel lesen | |
| 27.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.05.2025 | 666 | Xetra Newsboard | Das Instrument 6RJ US7731221062 ROCKET LAB USA A DL-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 27.05.2025 The instrument 6RJ US7731221062 ROCKET LAB USA A DL-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| 26.05. | Reverse Split and Change of ISIN for Annexin Pharmaceuticals AB | 491 | GlobeNewswire | Referring to the press release from Annexin Pharmaceuticals AB's on 21 May, the company will carry out a reverse stock split in relations 1:100. The share will be traded under new ISIN code with... ► Artikel lesen | |
| 03.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.03.2025 | 532 | Xetra Newsboard | Das Instrument MBG DE0007100000 MERCEDES-BENZ GRP NA O.N. EQUITY wird ex Kapitalmassnahme gehandelt am 03.03.2025 The instrument MBG DE0007100000 MERCEDES-BENZ GRP NA O.N. EQUITY is traded ex capital... ► Artikel lesen | |
| 06.02. | Annexin Pharmaceuticals AB: Annexin resolves on a rights issue of approximately SEK 50 million, secured to approximately 80 percent, subject to approval by the Extraordinary General Meeting | 371 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,180 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,82 | 0,00 % | Chardan Capital downgrades Avidity Biosciences stock on Novartis acquisition | ||
| RECURSION PHARMACEUTICALS | 4,630 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| MBX BIOSCIENCES | 25,570 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Reported positive topline results from the Phase 2 Avail trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross... ► Artikel lesen | |
| DISC MEDICINE | 83,85 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,520 | 0,00 % | ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales | ||
| EVOTEC | 5,314 | +1,49 % | Millionen für BioNTech und Evotec! Doch Medikamentenentwicklung kostet! Deshalb auf den Übernahmekandidaten NetraMark Aktie setzen!? | Nächste Erfolgsmeldung für NetraMark. Die KI des Unternehmens hat das nächste Biopharmaunternehmen überzeugt und wird immer mehr zum Übernahmekandidaten. Der neue Kunde will mit NetraAI seine klinische... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 38,370 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| BIONTECH | 90,25 | +1,12 % | BioNTech investiert Milliarden: Kommt jetzt die Trendwende? | Nach einer langen Durststrecke sendet BioNTech endlich wieder positive Signale - und überrascht mit einer deutlichen Prognosekorrektur nach oben. Während die Pandemie-Zeiten endgültig der Vergangenheit... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,350 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 8,200 | 0,00 % | Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved... ► Artikel lesen | |
| QIAGEN | 37,615 | +0,75 % | QIAGEN zahlt rund 500 Mio. USD durch synthetischen Aktienrückkauf an seine Aktionäre zurück | Venlo (NL) (www.anleihencheck.de) - QIAGEN zahlt rund 500 Mio. USD durch synthetischen Aktienrückkauf an seine Aktionäre zurück - AnleihenewsQIAGEN N.V. (ISIN NL0015002CX3/ WKN A40ZZU) gibt Pläne bekannt... ► Artikel lesen | |
| JANUX THERAPEUTICS | 26,470 | 0,00 % | Janux Therapeutics GAAP EPS of -$0.39 beats by $0.23, revenue of $10M beats by $6.93M | ||
| CG ONCOLOGY | 39,680 | 0,00 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 168,41 | 0,00 % | Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline |
ANNEXIN PHARMACEUTICALS AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,380 Euro und damit +2,59 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.